Clinical Trials
Metastatic Prostate Cancer That No longer Responds to Androgen Deprivation Treatment (mCRPC)

This Information is provided to help patients identify clinical trials for educational purposes and not to recruit patients for any specific trials. Patients should consult with their personal doctor and the trial sponsors for additional information on trials of interest.

Study of Gene Therapy + Valacyclovir in Combination With Brachytherapy for Recurrent Prostate Cancer

Number: NCT01913106
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The Methodist Hospital System
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Enzalutamide and Mifepristone in Treating Patients With Prostate Cancer

Number: NCT02012296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Chicago|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of a molecular inhibitor in patients with genetic mutations

Number: NCT02203513
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Radium-223 (Xofigo) for patients with mCRPC

Number: NCT02346526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 2
Sponsor(s): Massachusetts General Hospital|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study of Ribociclib in Combination With Docetaxel Plus Prednisone in mCRPC

Number: NCT02494921
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Number: NCT02499835
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Cabazitaxel in Treating Patients With mCRPC

Number: NCT02522715
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OHSU Knight Cancer Institute|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With and Without Ribociclib for mCRPC patients who have not received chemotherapy

Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s)
A study of Sirolimus, Docetaxel, and Carboplatin in Treating Patients With mCRPC

Number: NCT02565901
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Nivolumab and Ipilimumab in Treating Patients With mCRPC

Number: NCT02601014
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With mCRPC

Number: NCT02807805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Chong-xian Pan|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Number: NCT02854436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02881242
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Number: NCT02903160
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Icahn School of Medicine at Mount Sinai|Sanofi|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, Davis|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Rucaparib in Patients With mCRPC and Genetic Mutations

Number: NCT02952534
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Clovis Oncology, Inc.|Foundation Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Number: NCT02975934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Clovis Oncology, Inc.|Foundation Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Number: NCT02985021
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seattle Institute for Biomedical and Clinical Research|Prostate Cancer Foundation|VA Puget Sound Health Care System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer

Number: NCT02985957
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TRC253, an Androgen Receptor Antagonist in mCRPC Patients

Number: NCT02987829
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tracon Pharmaceuticals Inc.|Janssen Pharmaceutica N.V., Belgium
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab in Combination With Intratumoral SD-101 Therapy

Number: NCT03007732
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Lawrence Fong|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With mCRPC With DNA Repair Defects

Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Treatment with Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer

Number: NCT03069937
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|Ferring Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With mCRPC

Number: NCT03098836
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Daniel George, MD|Janssen Scientific Affairs, LLC|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Talazoparib in Men With DNA Repair Defects and mCRPC

Number: NCT03148795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Pfizer|Medivation, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Using Imaging for Detection of mCRPC

Number: NCT03173924
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Number: NCT03246347
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Earle Burgess|Astellas Pharma Inc|Medivation, Inc.|Carolinas Healthcare System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab in mCRPC With or Without DNA Damage Repair Defects

Number: NCT03248570
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Number: NCT03263650
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|AstraZeneca|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Number: NCT03298087
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

Number: NCT03304418
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Number: NCT03330405
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in mCRPC

Number: NCT03338790
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb|Clovis Oncology|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients

Number: NCT03360721
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR)

Number: NCT03395197
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Number: NCT03409458
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics|Pfizer|EMD Serono
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Number: NCT03413995
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With mCRPC

Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Trovagene, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel

Number: NCT03419234
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Niraparib Combination Therapies for the Treatment of mCRPC

Number: NCT03431350
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Navarixin in Combination With Pembrolizumab in Adults With Selected Advanced/Metastatic Solid Tumors

Number: NCT03473925
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03480646
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Constellation Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)

Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Number: NCT03495427
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer

Number: NCT03516812
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
COMbination of Bipolar Androgen Therapy and Nivolumab

Number: NCT03554317
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Number: NCT03556904
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Michigan Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Number: NCT03570619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Michigan Cancer Center|Memorial Sloan Kettering Cancer Center|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Number: NCT03678025
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Southwest Oncology Group|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Number: NCT03706365
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 2
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s)
Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Number: NCT03712930
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): BeiGene
Sponsor Trial Information
Trial Location(s) and Contact(s)
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Number: NCT03725761
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)|Immunomedics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study on Olaparib Plus A Study of Abiraterone as in Men with mCPRC

Number: NCT03732820
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 3
Sponsor(s): AstraZeneca|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

Number: NCT03748641
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Apalutamide in Participants With High Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Number: NCT03767244
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Avelumab Plus ADT in African American Subjects with mCRPC

Number: NCT03770455
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: 2
Sponsor(s): EMD Serono|Tulane University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with MCRPC

Number: NCT03792841
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Number: NCT03834493
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Number: NCT03834506
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Number: NCT03834519
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s)
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Number: NCT03951831
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Mark Stein|Regeneron Pharmaceuticals|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Number: NCT04028388
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Modra Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04033432
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|Vasgene Therapeutics, Inc|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Number: NCT04089553
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Number: NCT04090775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rampart Health, L.L.C.
Sponsor Trial Information
Trial Location(s) and Contact(s)

Total: 74 Clinical Trials

























PHEN,Inc. © 2019 All rights reserved